163 related articles for article (PubMed ID: 29251621)
81. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
82. NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies.
Kröger N; Bacher U; Bader P; Böttcher S; Borowitz MJ; Dreger P; Khouri I; Olavarria E; Radich J; Stock W; Vose JM; Weisdorf D; Willasch A; Giralt S; Bishop MR; Wayne AS
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1325-46. PubMed ID: 20637879
[TBL] [Abstract][Full Text] [Related]
83. Qualitative assessment of mixed chimerism after allogeneic bone marrow transplantation with regard to leukemic relapse.
Kögler G; Hernandez A; Heyll A; Wolf HH; Wernet P
Cancer Detect Prev; 1996; 20(6):601-9. PubMed ID: 8939346
[TBL] [Abstract][Full Text] [Related]
84. Kinetics of plasma-cell chimerism after allogeneic stem cell transplantation by highly sensitive real-time PCR based on sequence polymorphism and its value to quantify minimal residual disease in patients with multiple myeloma.
Kröger N; Zagrivnaja M; Schwartz S; Badbaran A; Zabelina T; Lioznov M; Ayuk F; Zander A; Fehse B
Exp Hematol; 2006 May; 34(5):688-94. PubMed ID: 16647575
[TBL] [Abstract][Full Text] [Related]
85. Donor Lymphocyte Infusions Used to Treat Mixed-Chimeric and High-Risk Patient Populations in the Relapsed and Nonrelapsed Settings after Allogeneic Transplantation for Hematologic Malignancies Are Associated with High Five-Year Survival if Persistent Full Donor Chimerism Is Obtained or Maintained.
Caldemeyer LE; Akard LP; Edwards JR; Tandra A; Wagenknecht DR; Dugan MJ
Biol Blood Marrow Transplant; 2017 Nov; 23(11):1989-1997. PubMed ID: 28712934
[TBL] [Abstract][Full Text] [Related]
86. Acute GVHD is a strong predictor of full donor CD3+ T cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation.
El-Cheikh J; Vazquez A; Crocchiolo R; Furst S; Calmels B; Castagna L; Lemarie C; Granata A; Ladaique P; Oudin C; Faucher C; Chabannon C; Blaise D
Am J Hematol; 2012 Dec; 87(12):1074-8. PubMed ID: 22911907
[TBL] [Abstract][Full Text] [Related]
87. Validation of next-generation sequencing-based chimerism testing for accurate detection and monitoring of engraftment in hematopoietic stem cell transplantation.
Kakodkar P; Zhao Y; Pan H; Wu F; Pearce T; Webster D; Elemary M; Sabry W; Kwan L; Pelzer L; Bosch M; Sherwood KR; Lan J; Tran J; Liwski R; Keown P; Mostafa A
Front Genet; 2023; 14():1282947. PubMed ID: 37937195
[TBL] [Abstract][Full Text] [Related]
88. Assessment of Minimal Residual Disease by Next Generation Sequencing in Peripheral Blood as a Complementary Tool for Personalized Transplant Monitoring in Myeloid Neoplasms.
Aguirre-Ruiz P; Ariceta B; Viguria MC; Zudaire MT; Blasco-Iturri Z; Arnedo P; Aguilera-Diaz A; Jauregui A; Mañú A; Prosper F; Mateos MC; Fernández-Mercado M; Larráyoz MJ; Redondo M; Calasanz MJ; Vázquez I; Bandrés E
J Clin Med; 2020 Nov; 9(12):. PubMed ID: 33255857
[TBL] [Abstract][Full Text] [Related]
89. Is microchimerism a sign of imminent disease recurrence after allogeneic hematopoietic stem cell transplantation? A systematic review of the literature.
Haugaard AK; Kofoed J; Masmas TN; Madsen HO; Marquart HV; Heilmann C; Müller KG; Ifversen M
Blood Rev; 2020 Nov; 44():100673. PubMed ID: 32173088
[TBL] [Abstract][Full Text] [Related]
90. Monitoring of hematopoietic chimerism by real-time quantitative PCR of micro insertions/deletions in samples with low DNA quantities.
Bach C; Tomova E; Goldmann K; Weisbach V; Roesler W; Mackensen A; Winkler J; Spriewald BM
Transfus Med Hemother; 2015 Jan; 42(1):38-45. PubMed ID: 25960714
[TBL] [Abstract][Full Text] [Related]
91. Monitoring of Measurable Residual Disease Using Circulating DNA after Allogeneic Hematopoietic Cell Transplantation.
Waterhouse M; Pennisi S; Pfeifer D; Scherer F; Zeiser R; Duyster J; Bertz H; Finke J; Duque-Afonso J
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884368
[TBL] [Abstract][Full Text] [Related]
92. Optimizing Donor Chimerism Threshold for Next-Generation Sequencing Monitoring of Measurable Residual Disease Post-Allogeneic Stem Cell Transplantation for Myeloid Neoplasms.
Puzo CJ; Tormey CA; Rinder HM; Siddon AJ
Transplant Cell Ther; 2023 Jul; 29(7):459.e1-459.e4. PubMed ID: 37062510
[TBL] [Abstract][Full Text] [Related]
93. Chimerism Analysis of Cell-Free DNA in Patients Treated with Hematopoietic Stem Cell Transplantation May Predict Early Relapse in Patients with Hematologic Malignancies.
Aljurf M; Abalkhail H; Alseraihy A; Mohamed SY; Ayas M; Alsharif F; Alzahrani H; Al-Jefri A; Aldawsari G; Al-Ahmari A; Belgaumi AF; Walter CU; El-Solh H; Rasheed W; Albitar M
Biotechnol Res Int; 2016; 2016():8589270. PubMed ID: 27006832
[TBL] [Abstract][Full Text] [Related]
94. Dangers resulting from DNA profiling of biological materials derived from patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT) with regard to forensic genetic analysis.
Jacewicz R; Lewandowski K; Rupa-Matysek J; Jędrzejczyk M; Berent J
Arch Med Sadowej Kryminol; 2015; 65(4):225-47. PubMed ID: 27543957
[TBL] [Abstract][Full Text] [Related]
95. Chimerism Assay Using Single Nucleotide Polymorphisms Adjacent and in Linkage-Disequilibrium Enables Sensitive Disease Relapse Monitoring after Hematopoietic Stem-Cell Transplantation.
Kim J; Yun W; Park YJ; Seo J; Lee RDW; Shin S; Lee HJ; Kim IS; Choi JR; Lee ST
Clin Chem; 2021 Apr; 67(5):781-787. PubMed ID: 33582770
[TBL] [Abstract][Full Text] [Related]
96. Methods and role of minimal residual disease after stem cell transplantation.
Ladetto M; Böttcher S; Kröger N; Pulsipher MA; Bader P
Bone Marrow Transplant; 2019 May; 54(5):681-690. PubMed ID: 30116018
[TBL] [Abstract][Full Text] [Related]
97. Donor Chimerism Study by Single Nucleotide Polymorphism using SYBR green based Real Time PCR.
Nayyar A; Ahmed S
Pak J Med Sci; 2021; 37(7):1795-1799. PubMed ID: 34912397
[TBL] [Abstract][Full Text] [Related]
98. Hematopoietic chimerism after allogeneic stem cell transplantation: a comparison of quantitative analysis by automated DNA sizing and fluorescent in situ hybridization.
Jólkowska J; Pieczonka A; Strabel T; Boruczkowski D; Wachowiak J; Bader P; Witt M
BMC Blood Disord; 2005 Jan; 5(1):1. PubMed ID: 15642114
[TBL] [Abstract][Full Text] [Related]
99. Minimal residual disease.
Lion T
Curr Opin Hematol; 1999 Nov; 6(6):406-11. PubMed ID: 10546795
[TBL] [Abstract][Full Text] [Related]
100. Chimerism Monitoring Techniques after Hematopoietic Stem Cell Transplantation: An Overview of the Last 15 Years of Innovations.
Tozzo P; Delicati A; Zambello R; Caenazzo L
Diagnostics (Basel); 2021 Mar; 11(4):. PubMed ID: 33808342
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
